Document is current
Any future updates will be listed below
-
Authors
Azar, Pouya
Ignaszewski, Martha J.
Harris, Marianne
Barazanci, Zoran
Davison, Ruth
Wong, James S. H.
Maharaj, Anil
Mathew, Nickie
Hall, David
Guillemi, Silvia A.
Foreman, Julie
Barrios, Rolando
Montaner, Julio S. G.
-
Funding
Funding for this research was provided by:
Health Canada Substance Use and Addictions Program (2021-HQ-000060, 2021-HQ-000060, 2021-HQ-000060, 2021-HQ-000060, 2021-HQ-000060, 2021-HQ-000060, 2021-HQ-000060, 2021-HQ-000060, 2021-HQ-000060, 2021-HQ-000060, 2021-HQ-000060, 2021-HQ-000060, 2021-HQ-000060)
- License Information
-
More Information
Article History
Received: 7 October 2024
Accepted: 14 July 2025
First Online: 29 July 2025
Declarations
:
: The study protocol and informed consent form were approved by the University of British Columbia/Providence Health Care Research Ethics Board (H23-00111). The investigators will inform the UBC/PHC REB about the progress of the study and any protocol amendments will be submitted for REB approval before implementation. The investigators will notify the REB of any significant protocol deviations, unanticipated problems, or serious adverse events that may occur during the course of the study.
: See Supplementary Materials for the approved informed consent document.
: PA was a consultant on Indivior-led buprenorphine extended-release studies, and has received speaking honoraria for Indivior-funded buprenorphine presentations, both of which are unrelated to this study protocol. MJI has received honoraria from Indivior, unrelated to this study protocol. The other authors declare that they have have no competing interests.
